Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) General Counsel Sells $55,566.16 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) General Counsel Adam Dubow sold 4,646 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $55,566.16. Following the completion of the sale, the general counsel now directly owns 39,602 shares in the company, valued at approximately $473,639.92. This represents a 10.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Day One Biopharmaceuticals Trading Up 1.6 %

Day One Biopharmaceuticals stock opened at $12.43 on Monday. Day One Biopharmaceuticals, Inc. has a 1-year low of $11.13 and a 1-year high of $18.07. The firm has a market capitalization of $1.25 billion, a price-to-earnings ratio of -12.07 and a beta of -1.46. The firm’s fifty day moving average price is $12.37 and its two-hundred day moving average price is $13.48.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. bought a new position in shares of Day One Biopharmaceuticals in the fourth quarter valued at $27,000. R Squared Ltd bought a new position in shares of Day One Biopharmaceuticals during the fourth quarter valued at about $31,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Day One Biopharmaceuticals by 38.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock valued at $51,000 after purchasing an additional 1,002 shares in the last quarter. Quest Partners LLC lifted its position in shares of Day One Biopharmaceuticals by 9,238.6% during the third quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock valued at $108,000 after purchasing an additional 7,668 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in shares of Day One Biopharmaceuticals by 911.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company’s stock valued at $135,000 after purchasing an additional 9,603 shares in the last quarter. 87.95% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on DAWN. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. Bank of America cut their target price on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. The Goldman Sachs Group cut their target price on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating on the stock in a research note on Monday, February 10th. Needham & Company LLC reissued a “buy” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, January 13th. Finally, TD Cowen raised shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $35.71.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.